These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23610115)

  • 1. Case of sorafenib-induced thyroid storm.
    Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
    J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE; Watson AC; Aronson P
    Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable spontaneous regression of lung metastases from renal cell carcinoma after incomplete use of multiple kinase inhibitor sorafenib.
    Hegde U; Patel V; Kaloudis E
    Int J Urol; 2013 Jun; 20(6):644-5. PubMed ID: 23186003
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
    El Tal AK; Remichofsky CJ; Mehregan DA; Ganger LK
    Int J Dermatol; 2013 Dec; 52(12):1538-41. PubMed ID: 23676092
    [No Abstract]   [Full Text] [Related]  

  • 5. [Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
    Takagi K; Takai M; Kawata K; Horie K; Kikuchi M; Kato T; Mizutani K; Seike K; Tsuchiya T; Yasuda M; Yokoi S; Nakano M; Ushikoshi H; Miyazaki T; Deguchi T
    Hinyokika Kiyo; 2015 Sep; 61(9):347-51. PubMed ID: 26497860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed onset perforating folliculitis associated with sorafenib.
    Batalla A; Menéndez L; Blay P; Curto JR
    Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
    İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
    J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
    [No Abstract]   [Full Text] [Related]  

  • 8. Education and imaging. Hepatology: Complete regression of locally advanced hepatocellular carcinoma following Sorafenib monotherapy.
    Kumar S
    J Gastroenterol Hepatol; 2015 Mar; 30(3):438. PubMed ID: 25707790
    [No Abstract]   [Full Text] [Related]  

  • 9. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
    Kashima T; Ohno Y; Tachibana M
    Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
    [No Abstract]   [Full Text] [Related]  

  • 10. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
    Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
    Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitor induced pancreatitis.
    Sevin A; Chen A; Atkinson B
    J Oncol Pharm Pract; 2013 Sep; 19(3):257-60. PubMed ID: 23034406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.
    Wolter P; Beuselinck B; Pans S; Schöffski P
    Acta Oncol; 2009; 48(4):621-4. PubMed ID: 19107622
    [No Abstract]   [Full Text] [Related]  

  • 13. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
    Dasanu CA; Alexandrescu DT; Dutcher J
    South Med J; 2007 Mar; 100(3):328-30. PubMed ID: 17396743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation recall dermatitis induced by sorafenib : A case study and review of the literature.
    Stieb S; Riesterer O; Brüssow C; Pestalozzi B; Guckenberger M; Weiler S
    Strahlenther Onkol; 2016 May; 192(5):342-8. PubMed ID: 26907093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic atrophy--a new late toxic effect of sorafenib.
    Hescot S; Vignaux O; Goldwasser F
    N Engl J Med; 2013 Oct; 369(15):1475-6. PubMed ID: 24106956
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.
    Konca Degertekin C; Coşkun U; Baloş Törüner F; Aktürk M; Demirci U
    Endocrine; 2012 Dec; 42(3):756-7. PubMed ID: 22562706
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
    Callaghan C; Peralta D; Liu J; Mandava SH; Maddox M; Dash S; Tarr MA; Lee BR
    J Pharm Sci; 2016 Jan; 105(1):284-92. PubMed ID: 26852860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 - AN 33/11)].
    Rexer H;
    Urologe A; 2014 May; 53(5):735-8. PubMed ID: 24727992
    [No Abstract]   [Full Text] [Related]  

  • 19. Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma.
    Hsiao YW; Lin YC; Hui RC; Yang CH
    J Clin Oncol; 2011 Apr; 29(12):e340-1. PubMed ID: 21263088
    [No Abstract]   [Full Text] [Related]  

  • 20. Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.
    Fairfax BP; Pratap S; Roberts IS; Collier J; Kaplan R; Meade AM; Ritchie AW; Eisen T; Macaulay VM; Protheroe A
    BMC Cancer; 2012 Dec; 12():590. PubMed ID: 23231599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.